0001209191-23-054733.txt : 20231108
0001209191-23-054733.hdr.sgml : 20231108
20231108180909
ACCESSION NUMBER: 0001209191-23-054733
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231106
FILED AS OF DATE: 20231108
DATE AS OF CHANGE: 20231108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WOODHOUSE DAVID J
CENTRAL INDEX KEY: 0001642995
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38853
FILM NUMBER: 231389484
MAIL ADDRESS:
STREET 1: 630 GATEWAY BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NGM BIOPHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001426332
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 333 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-243-5555
MAIL ADDRESS:
STREET 1: 333 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-11-06
0
0001426332
NGM BIOPHARMACEUTICALS INC
NGM
0001642995
WOODHOUSE DAVID J
C/O NGM BIOPHARMACEUTICALS, INC.
333 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
Chief Executive Officer
0
Stock Option (Right to Buy)
0.84
2023-11-06
4
A
0
255000
A
2025-04-21
Common Stock
255000
255000
D
Stock Option (Right to Buy)
7.54
2023-11-06
4
D
0
255000
D
2025-04-21
Common Stock
255000
0
D
Stock Option (Right to Buy)
0.84
2023-11-06
4
A
0
87013
A
2027-01-19
Common Stock
87013
87013
D
Stock Option (Right to Buy)
7.70
2023-11-06
4
D
0
87013
D
2027-01-19
Common Stock
87013
0
D
Stock Option (Right to Buy)
0.84
2023-11-06
4
A
0
57833
A
2028-01-30
Common Stock
57833
57833
D
Stock Option (Right to Buy)
8.14
2023-11-06
4
D
0
57833
D
2028-01-30
Common Stock
57833
0
D
Stock Option (Right to Buy)
0.84
2023-11-06
4
A
0
500000
A
2028-07-24
Common Stock
500000
500000
D
Stock Option (Right to Buy)
11.00
2023-11-06
4
D
0
500000
D
2028-07-24
Common Stock
500000
0
D
Stock Option (Right to Buy)
0.84
2023-11-06
4
A
0
200000
A
2029-02-06
Common Stock
200000
200000
D
Stock Option (Right to Buy)
12.06
2023-11-06
4
D
0
200000
D
2029-02-06
Common Stock
200000
0
D
Stock Option (Right to Buy)
0.84
2023-11-06
4
A
0
400000
A
2030-02-03
Common Stock
400000
400000
D
Stock Option (Right to Buy)
16.47
2023-11-06
4
D
0
400000
D
2030-02-03
Common Stock
400000
0
D
Stock Option (Right to Buy)
0.84
2023-11-06
4
A
0
450000
A
2031-03-16
Common Stock
450000
450000
D
Stock Option (Right to Buy)
31.93
2023-11-06
4
D
0
450000
D
2031-03-16
Common Stock
450000
0
D
Stock Option (Right to Buy)
0.84
2023-11-06
4
A
0
500000
A
2032-03-02
Common Stock
500000
500000
D
Stock Option (Right to Buy)
15.20
2023-11-06
4
D
0
500000
D
2032-03-02
Common Stock
500000
0
D
Fully vested.
Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the "Company") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged.
The shares subject to the stock option vest over a four-year period commencing January 1, 2020, with 1/48th of the shares vesting on a monthly basis.
The shares subject to the stock option vest over a four-year period commencing January 1, 2021, with 1/48th of the shares vesting on a monthly basis.
The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis.
/s/ Valerie Pierce, Attorney-in-fact
2023-11-08